Department of Veterans Affairs Cooperative Study on Anti- platelet Therapy. J Am Coll Cardiol. 1990;15:15 20. 536. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002;324:71 86. 537. Lorenz RL, Schacky CV, Weber M, et al. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet. 1984;1:1261 4. 538. Sharma GV, Khuri SF, Josa M, et al. The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency. Circulation. 1983;68:II218 21. 539. Stein PD, Schunemann HJ, Dalen JE, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Throm- bolytic Therapy. Chest. 2004;126:600S 8S. 540. Goldman S, Copeland J, Moritz T, et al. Internal mammary artery and saphenous vein graft patency. Effects of aspirin. Circulation. 1990;82: IV237 42. 541. Lim E, Ali Z, Ali A, et al. Indirect comparison meta-analysis of aspirin therapy after coronary surgery [published correction appears in BMJ. 2004;328:147]. BMJ. 2003;327:1309. 542. Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46:1258 63. 543. Limet R, David JL, Magotteaux P, et al. Prevention of aorta-coronary bypass graft occlusion. beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg. 1987;94:773 83. 544. Veeger NJ, Zijlstra F, Hillege HL, et al. Fourteen-year follow-up from CABADAS: vitamin K antagonists or dipyridamole not superior to aspirin. Ann Thorac Surg. 2010;90:1515 21. 545. The Post Coronary Artery Bypass Graft Trial Investigators. 